We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
Read MoreHide Full Article
Key Takeaways
CELC filed an NDA for gedatolisib in HR , HER2- advanced breast cancer, with an FDA decision due in 2026.
Phase III VIKTORIA-1 data showed strong PFS gains, supporting gedatolisib as a second-line option.
Celcuity completed enrollment in another VIKTORIA-1 cohort, with more cancer studies underway.
Celcuity (CELC - Free Report) has made significant clinical and regulatory progress in the past few months. In November, Celcuity submitted a new drug application (“NDA”) to the FDA seeking approval for its lead pipeline candidate, gedatolisib, for patients with HR+, HER2- advanced breast cancer who have received prior treatment with a CDK4/6 inhibitor. The FDA decision on the NDA is expected in 2026 and Celcuity has accelerated its commercial launch preparation.
Gedatolisib is a multi-target PAM inhibitor that comprehensively blocks the PAM pathway, differentiating it from currently approved single-target inhibitors of the PAM pathway.
The NDA was based on data from the PIK3CA wild-type cohort of the phase III VIKTORIA-1 study, which demonstrated the potential of gedatolisib as a new standard of care second-line therapy for patients with HR-positive, HER2-negative advanced breast cancer. In October, Celcuity announced positive top-line data from the PIK3CA wild-type cohort of the VIKTORIA-1 study. The data showed that the gedatolisib triplet and doublet achieved 7.3 and 5.4 months of incremental improvements in median progression-free survival, or PFS, over fulvestrant, respectively. The PFS improvements were greater than those reported by any phase III study for patients with HR+, HER2- advanced breast cancer receiving at least their second line of endocrine therapy.
There is a significant unmet need for more efficacious therapies than those currently available for patients with HR+, HER2- advanced breast cancer who have been previously given a CDK4/6 inhibitor. Celcuity's unprecedented efficacy results in this patient population and completion of the NDA filing led the stock to rise 677.4% in six months, outperforming the industry’s increase of 21.5%.
Image Source: Zacks Investment Research
Enrollment is complete in the PIK3CA mutant cohort of the VIKTORIA-1 study. Top-line data from this cohort is expected in the first half of 2026. Additional studies are ongoing on gedatolisib combinations in breast cancer and prostate cancer.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 adjusted EPS have increased from $7.81 to $8.08 per share. Shares of ANIP have surged 44.6% in the past year.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.
Over the past 60 days, estimates for CorMedix’s 2026 EPS have increased from $2.49 to $2.88. Shares of CRMD have surged 18.5% over the past year.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 EPS have declined from 70 cents to 65 cents. Shares of FOLD have surged 52.3% over the past year.
Amicus Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining quarter, with the average negative surprise being 20.21%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
Key Takeaways
Celcuity (CELC - Free Report) has made significant clinical and regulatory progress in the past few months. In November, Celcuity submitted a new drug application (“NDA”) to the FDA seeking approval for its lead pipeline candidate, gedatolisib, for patients with HR+, HER2- advanced breast cancer who have received prior treatment with a CDK4/6 inhibitor. The FDA decision on the NDA is expected in 2026 and Celcuity has accelerated its commercial launch preparation.
Gedatolisib is a multi-target PAM inhibitor that comprehensively blocks the PAM pathway, differentiating it from currently approved single-target inhibitors of the PAM pathway.
The NDA was based on data from the PIK3CA wild-type cohort of the phase III VIKTORIA-1 study, which demonstrated the potential of gedatolisib as a new standard of care second-line therapy for patients with HR-positive, HER2-negative advanced breast cancer. In October, Celcuity announced positive top-line data from the PIK3CA wild-type cohort of the VIKTORIA-1 study. The data showed that the gedatolisib triplet and doublet achieved 7.3 and 5.4 months of incremental improvements in median progression-free survival, or PFS, over fulvestrant, respectively. The PFS improvements were greater than those reported by any phase III study for patients with HR+, HER2- advanced breast cancer receiving at least their second line of endocrine therapy.
There is a significant unmet need for more efficacious therapies than those currently available for patients with HR+, HER2- advanced breast cancer who have been previously given a CDK4/6 inhibitor. Celcuity's unprecedented efficacy results in this patient population and completion of the NDA filing led the stock to rise 677.4% in six months, outperforming the industry’s increase of 21.5%.
Image Source: Zacks Investment Research
Enrollment is complete in the PIK3CA mutant cohort of the VIKTORIA-1 study. Top-line data from this cohort is expected in the first half of 2026. Additional studies are ongoing on gedatolisib combinations in breast cancer and prostate cancer.
Zacks Rank and Stocks to Consider
Celcuity has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) , CorMedix (CRMD - Free Report) and Amicus Therapeutics (FOLD - Free Report) . ANIP, CRMD and FOLD currently sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 adjusted EPS have increased from $7.81 to $8.08 per share. Shares of ANIP have surged 44.6% in the past year.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.
Over the past 60 days, estimates for CorMedix’s 2026 EPS have increased from $2.49 to $2.88. Shares of CRMD have surged 18.5% over the past year.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 EPS have declined from 70 cents to 65 cents. Shares of FOLD have surged 52.3% over the past year.
Amicus Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining quarter, with the average negative surprise being 20.21%.